Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINE 1
2023-505755-40-00Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing BAY 3283142 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 16 in log-transformed urine albumin-creatinine ratio (UACR). Started Aug 2024; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-505755-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505755-40-00.